Prospective meta-analysis of randomised trials of cyclophosphamide, methotrexate & fluorouracil (CMF) vs fluorouracil, epirubicin & cyclophosphamide (FEC) chemotherapy in early breast cancer

被引：0
|
作者：
Marty, ME
Coombes, RC
Peckitt, C
López, FRP
Tres, A
Morvan, F
Tubiana-Mathieu, N
Espié, M
Bliss, JM
机构：
[1] Univ London Imperial Coll Sci Technol & Med, London, England
[2] Inst Gustave Roussy, Villejuif, France
[3] Univ London Imperial Coll Sci Technol & Med, CR UK Labs, London, England
[4] Canc Res Inst, Sutton, Surrey, England
[5] Hosp Clin Zaragoza, Zaragoza, Spain
[6] Ctr Hosp Rene Dubos, Pontoise, France
[7] Hop Dupuytren, Limoges, France
[8] Hop St Louis, Paris, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
592
引用
收藏
页码：25S / 25S
页数：1
相关论文
共 50 条
  • [41] MTHFR gene polymorphism and severe toxicity during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil (CMF)
    Toffoli, G
    Veronesi, A
    Boiocchi, M
    Crivellari, D
    ANNALS OF ONCOLOGY, 2000, 11 (03) : 373 - 374
  • [42] Concurrent cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy and radiotherapy for early breast carcinoma
    Livi, Lorenzo
    Saieva, Calogero
    Borghesi, Simona
    Paoletti, Lisa
    Meattini, Icro
    Rampini, Andrea
    Petrucci, Alessia
    Scoccianti, Silvia
    Paiar, Fabiola
    Cataliotti, Luigi
    Leonulli, Barbara Grilli
    Bianchi, Simonetta
    Biti, Gian Paolo
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 71 (03): : 705 - 709
  • [43] Mortality during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil
    Colleoni, M
    Price, KN
    Castiglione-Gertsch, M
    Gelber, RD
    Coates, AS
    Goldhirsch, A
    LANCET, 1999, 354 (9173): : 130 - 131
  • [44] NEOADJUVANT CHEMOTHERAPY WITH CYCLOPHOSPHAMIDE, DOXORUBICIN AND 5-FLUOROURACIL (CAF) OR CYCLOPHOSPHAMIDE, METHOTREXATE AND 5-FLUOROURACIL (CMF) IN 69 CASES OF LOCALLY ADVANCED (STAGE-IIIB) BREAST-CANCER
    GUPTA, P
    BIJLANI, L
    RATH, GK
    MISRA, A
    MISHRA, MC
    SHUKLA, NK
    KRIPLANI, A
    KAPUR, BML
    JAPANESE JOURNAL OF SURGERY, 1991, 21 (06): : 637 - 642
  • [45] CORRELATION OF ESTROGEN-RECEPTORS AND RESPONSE TO CHEMOTHERAPY OF CYCLOPHOSPHAMIDE, METHOTREXATE, AND 5-FLUOROURACIL (CMF) IN ADVANCED BREAST-CANCER
    CHANG, JC
    WERGOWSKE, G
    CANCER, 1981, 48 (11) : 2503 - 2506
  • [46] Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil:: Danish Breast Cancer Cooperative Group
    Knoop, AS
    Knudsen, H
    Balslev, E
    Rasmussen, BB
    Overgaard, J
    Nielsen, KV
    Schonau, A
    Gunnarsdóttir, K
    Olsen, KE
    Mouridsen, H
    Ejlertsen, B
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (30) : 7483 - 7490
  • [47] Prospective randomized study of neoadjuvant chemotherapy (NACT) with paclitaxel/epirubicin (PE) versus fluorouracil/epirubicin/cyclophosphamide (FEC) in operable stage II-IIIA breast cancer (BC)
    Malamos, N
    Kosmas, C
    Antonopoulos, MJ
    Tsikkinis, A
    Pallis, L
    Papadiamantis, J
    Kouri, E
    Vasilaros, S
    ANNALS OF ONCOLOGY, 1998, 9 : 22 - 23
  • [48] ADJUVANT CHEMOTHERAPY OF BREAST CANCERS BY AN ASSOCIATION OF CYCLOPHOSPHAMIDE, VINCRISTINE, METHOTREXATE AND FLUOROURACIL
    SWIERCZ, P
    SCHAERER, R
    MOUSSEAU, M
    GABELLE, P
    KOLODIE, H
    VINCENT, F
    BOLLA, M
    BULLETIN DU CANCER, 1982, 69 (04) : 368 - 368
  • [49] Phase III trial of cyclophosphamide, epirubicin, fluorouracil (CEF) versus cyclophosphamide, mitoxantrone, fluorouracil (CNF) in women with metastatic breast cancer
    Esteban, E
    Lacave, AJ
    Fernández, JL
    Corral, N
    Buesa, JM
    Estrada, E
    Palacio, I
    Vieitez, JM
    Muñiz, I
    Alvarez, E
    BREAST CANCER RESEARCH AND TREATMENT, 1999, 58 (02) : 141 - 150
  • [50] Phase III trial of cyclophosphamide, epirubicin, fluorouracil (CEF) versus cyclophosphamide, mitoxantrone, fluorouracil (CNF) in women with metastatic breast cancer
    E. Esteban
    A.J. Lacave
    J.L. Fernández
    N. Corral
    J.M. Buesa
    E. Estrada
    I. Palacio
    J.M. Vieitez
    I. Muñiz
    E. Alvarez
    Breast Cancer Research and Treatment, 1999, 58 : 141 - 150
12345